Table 2.

Multivariate Cox regression model for disease‐free interval and melanoma‐specific survival in the entire cohort and in patients who underwent sentinel lymph node biopsy

Variable	Hazard ratio	95% CI	P value
Entire cohort (n = 4249)
Disease‐free interval
Sex (female vs male)	0.7	0.5‐0.8	0.006
Ulceration (presence vs absence)	2.4	1.3‐4.3	0.006
Others vs LMM	0.3	0.2‐0.9	0.031
≥0.8 mm vs <0.8 mm Breslow thickness	1.6	1.1‐3	0.01
Clark level (IV‐V vs II‐III)	3.1	2‐4.8	<0.001
Melanoma‐specific survival
Sex (female vs male)	0.4	0.2‐0.7	<0.001
Ulceration (presence vs absence)	2.9	1.4‐6.1	0.005
ALM vs LMM	15.1	2.3‐98.6	0.004
≥0.8 mm vs <0.8 mm Breslow	1.9	1.1‐3.2	0.021
Clark level (IV‐V vs II‐III)	3	1.6‐5.7	0.001
Patients underwent SLNB (n = 1090)
Disease‐free interval
Sex (female vs male)	0.5	0.3‐0.9	0.027
Age >5 vs <40	2.5	1.1‐5.7	0.028
Ulceration (presence vs absence)	3	1.5‐5.9	0.002
Clark level (IV‐V vs II‐III)	2.8	1.6‐4.9	<0.001
SLNB (positive vs negative)	7.4	4.1‐13.5	<0.001
Melanoma‐specific survival
Sex (female vs male)	0.3	0.1‐0.6	0.004
Age >65 vs <40	3.5	1‐12.1	0.044
Ulceration (presence vs absence)	4.3	1.7‐10.4	0.001
Clark level (IV‐V vs II‐III)	2.6	1.1‐6.1	0.022
SLNB (positive vs negative)	12.8	5.4‐30.2	<0.001

Abbreviations: ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma; SLNB: Sentinel lymph node biopsy.